Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Semaglutide, used for diabetes and obesity, may reduce alcohol cravings in adults with alcohol use disorder, offering a potential solution to a major treatment gap.

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

A clinical trial shows that people who were considered by medical researchers to report signs of alcohol use disorder drank significantly less after taking semaglutide for two months, compared to ...

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

A new clinical trial suggests that once-weekly semaglutide may reduce alcohol consumption and cravings in adults with alcohol use disorder.

A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...